Nebenwirkungen · Humira
Humira 20 mg solution for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 12
HOS-111727 · Präparat HOS-093595
Humira was studied in 9,506 patients in pivotal controlled and open label trials for up to 60 months or more. These trials included rheumatoid arthritis patients with short term and long standing disease, juvenile idiopathic arthritis (polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis) as well as axial spondyloarthritis (ankylosing spondylitis and axial spondyloarthritis without radiographic evidence of AS), psoriatic arthritis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa and uveitis patients. The pivotal controlled studies involved 6,089 patients receiving Humira and 3,801 patients receiving placebo or active comparator during the controlled period.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-08T11:41:00Z · SHA-256 0118f9ea31f7b28ac156bc8449293407c25bc43421a73fa92a30fe90db390eca · Passage 52828a33a39b5e2c569e3cff7565bd337d38795342d7a3dade7e083c952d3d1f · Zeichen 31–745 im Abschnitt